Differential in vivo inhibition of [3H]nemonapride binding by atypical antipsychotics in rat striatum, olfactory lobes, and frontal cortex.
Assié MB, Consul-Denjean N, Koek W, Newman-Tancredi A.
Pharmacology · journal article · DOI 10.1159/000086948 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för nemonapride. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
22 träffarPositron emission tomography and ex vivo and in vitro autoradiography studies on dopamine D2-like receptor degeneration in the quinolinic acid-lesioned rat striatum: comparison of [11C]raclopride, [11C]nemonapride and [11C]N-methylspiperone.
Ishiwata K, Ogi N, Hayakawa N, Umegaki H, Nagaoka T, Oda K, Toyama H, Endo K, Tanaka A, Senda M.
Nucl Med Biol · comparative study; research support, non-u.s. gov't; journal article · DOI 10.1016/s0969-8051(01)00307-9Associations between side effects of nemonapride and plasma concentrations of the drug and prolactin.
Kondo T, Ishida M, Tokinaga N, Mihara K, Yasui-Furukori N, Ono S, Kaneko S.
Prog Neuropsychopharmacol Biol Psychiatry · research support, non-u.s. gov't; journal article · DOI 10.1016/s0278-5846(01)00267-6Therapeutic spectrum of nemonapride and its relationship with plasma concentrations of the drug and prolactin.
Kondo T, Mihara K, Yasui N, Nagashima U, Ono S, Kaneko S, Ohkubo T, Osanai T, Sugawara K, Otani K.
J Clin Psychopharmacol · clinical trial; research support, non-u.s. gov't; journal article · DOI 10.1097/00004714-200008000-00003The relationship between dopamine D2 receptor polymorphism at the Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients.
Suzuki A, Mihara K, Kondo T, Tanaka O, Nagashima U, Otani K, Kaneko S.
Pharmacogenetics · research support, non-u.s. gov't; journal article · DOI 10.1097/00008571-200006000-00007No relationship between Taq1 a polymorphism of dopamine D(2) receptor gene and extrapyramidal adverse effects of selective dopamine D(2) antagonists, bromperidol, and nemonapride in schizophrenia: a preliminary study.
Mihara K, Suzuki A, Kondo T, Nagashima U, Ono S, Otani K, Kaneko S.
Am J Med Genet · clinical trial; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1002/1096-8628(20000612)96:3<422::aid-ajmg35>3.0.co;2-5Prolactin response to nemonapride, a selective antagonist for D2 like dopamine receptors, in schizophrenic patients in relation to Taq1A polymorphism of DRD2 gene.
Mihara K, Kondo T, Suzuki A, Yasui N, Nagashima U, Ono S, Otani K, Kaneko S.
Psychopharmacology (Berl) · research support, non-u.s. gov't; journal article · DOI 10.1007/s002139900364In vivo binding of [11C]nemonapride to sigma receptors in the cortex and cerebellum.
Ishiwata K, Senda M.
Nucl Med Biol · research support, non-u.s. gov't; journal article · DOI 10.1016/s0969-8051(99)00033-5Comparison of three PET dopamine D2-like receptor ligands, [11C]raclopride, [11C]nemonapride and [11C]N-methylspiperone, in rats.
Ishiwata K, Hayakawa N, Ogi N, Oda K, Toyama H, Endo K, Tanaka A, Senda M.
Ann Nucl Med · comparative study; research support, non-u.s. gov't; journal article · DOI 10.1007/bf03164856Quantitative ex vivo and in vitro receptor autoradiography using 11C-labeled ligands and an imaging plate: a study with a dopamine D2-like receptor ligand [11C]nemonapride.
Ishiwata K, Ogi N, Tanaka A, Senda M.
Nucl Med Biol · research support, non-u.s. gov't; journal article · DOI 10.1016/s0969-8051(98)00115-2Dopamine D4-like binding sites labeled by [3H]nemonapride include substantial serotonin 5-HT2A receptors in primate cerebral cortex.
Noda-Saita K, Matsumoto M, Hidaka K, Hatanaka K, Ohmori J, Okada M, Yamaguchi T.
Biochem Biophys Res Commun · journal article · DOI 10.1006/bbrc.1999.0220Characteristics and risk factors of acute dystonia in schizophrenic patients treated with nemonapride, a selective dopamine antagonist.
Kondo T, Otani K, Tokinaga N, Ishida M, Yasui N, Kaneko S.
J Clin Psychopharmacol · research support, non-u.s. gov't; journal article · DOI 10.1097/00004714-199902000-00009High-performance liquid chromatographic determination of nemonapride and desmethylnemonapride in human plasma using an electrochemical detection.
Nagasaki T, Ohkubo T, Sugawar K, Yasui N, Ohtani K, Kaneko S.
J Chromatogr B Biomed Sci Appl · journal article · DOI 10.1016/s0378-4347(98)00212-6The cataleptogenic effects of the neuroleptic nemonapride are attenuated by its 5-HT1A receptor agonist properties.
Prinssen EP, Kleven MS, Koek W.
Eur J Pharmacol · comparative study; journal article · DOI 10.1016/s0014-2999(98)00536-6The binding of both [3H]nemonapride and [3H]raclopride is increased in schizophrenia.
Marzella PL, Hill C, Keks N, Singh B, Copolov D.
Biol Psychiatry · journal article · DOI 10.1016/s0006-3223(96)00471-45-HT1A receptor agonist properties of the antipsychotic, nemonapride: comparison with bromerguride and clozapine.
Assié MB, Cosi C, Koek W.
Eur J Pharmacol · comparative study; journal article · DOI 10.1016/s0014-2999(97)01207-7Differential labeling of dopamine and sigma sites by [3H]nemonapride and [3H]raclopride in postmortem human brains.
Tang SW, Helmeste DM, Fang H, Li M, Vu R, Bunney W, Potkin S, Jones EG.
Brain Res · journal article · DOI 10.1016/s0006-8993(97)00461-7Multiple [3H]-nemonapride binding sites in calf brain.
Helmeste DM, Tang SW, Li M, Fang H.
Naunyn Schmiedebergs Arch Pharmacol · journal article · DOI 10.1007/pl00005023Nemonapride for the treatment of schizophrenia.
Satoh K, Someya T, Shibasaki M.
Am J Psychiatry · letter; clinical trial · DOI 10.1176/ajp.154.2.292aEffects of reserpine treatment on the dopamine receptor binding of [3H/11C]nemonapride in the mouse and rat brain.
Ishiwata K, Onoguchi K, Toyama H, Noguchi J, Senda M.
Ann Nucl Med · journal article · DOI 10.1007/bf03164753Effects of nemonapride on positive and negative symptoms of schizophrenia.
Satoh K, Someya T, Shibasaki M.
Int Clin Psychopharmacol · clinical trial; research support, non-u.s. gov't; journal article · DOI 10.1097/00004850-199612000-00010Neuroleptic malignant syndrome induced by nemonapride.
Kubota T.
Acta Neurol (Napoli) · journal article; case reports